HONG KONG, Oct 31 (Reuters) - Innovent Biologics climbed 2.3 percent in a Hong Kong debut closely watched as a test of investor appetite for Chinese biotechs after three rivals saw their shares slide post-listing.
The Chinese biotech - backed by mutual fund giant Fidelity and Singapore state investor Temasek Holdings - was trading at HK$14.3 on Wednesday morning, above its IPO price of HK$13.98.
It is the fourth listing under new rules in Hong Kong aimed at wooing early-stage drug developers.
Reporting by Julia Fioretti and Kane Wu; Editing by Edwina Gibbs
